Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Lung Cancers
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
$0.00
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
- Acute Myelogenous Leukemia
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy. The preferred treatment option for BPDCN is the CD123 targeted therapy tagraxofusp ersz. Tagraxofusp-ersz can be associated with potentially life-threatening capillary leak syndrome, and it is crucial to be aware of management strategies if utilizing this agent.
- CNS Cancers
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
Neuroradiologic evaluation, an important part of diagnosis and evaluation of the effectiveness of subsequent therapy, can be confounded by steroids administration used to alleviate symptoms of primary central nervous system lymphomas (PCNSL). These confounding, non-diagnostic results can delay therapies for PCNSL, which commonly consist of methotrexate-based induction and consolidation treatments. Even with therapy, more than half the cases will relapse or be refractory to therapy.
- Non-Hodgkin's Lymphoma
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens. Bispecific antibodies represent a novel treatment option for heavily pretreated FL, including disease relapse following CAR T-cell therapy.
- Non-Hodgkin's Lymphoma
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients. Recent data have shown that BTK inhibitor-based regimens result in favorable outcomes in patients with previously untreated classical MCL with TP53 mutation. Chimeric antigen receptor (CAR) T-cell therapy also results in favorable response rates in previously treated classical MCL with TP53 mutation.
- Systemic Light Chain Amyloidosis
- 0.25 AAPA Category 1 CME credit
- 0.25 ACPE contact hours
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC contact hours
- 0.25 Participation
$0.00
Chronic myeloid leukemia (CML) can affect individuals of reproductive age, and tyrosine kinase inhibitor (TKI) therapy is known to have teratogenic effects. Discontinuing TKI therapy during pregnancy poses a risk of recurrence. Shared decision making is recommended in the management of patients with CML during pregnancy. Options for fertility preservation and alternatives to TKI therapy should be discussed with all patients.
- Myeloproliferative Neoplasms
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF. Patients have a significant symptom burden and a propensity for disease transformation to accelerated and blast phases. For many years, ruxolitinib was the only FDA-approved drug for the treatment of intermediate-risk or high-risk MF. Since then, multiple new JAK inhibitors have been approved by the FDA.
- Systemic Light Chain Amyloidosis
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
High rates of early mortality in newly diagnosed systemic light-chain amyloidosis (SLCA) suggest that there continues to be a delay in early diagnosis. The initial evaluation must confirm the diagnosis, establish the extent and sites of disease, and evaluate for comorbidities that are likely to have an impact on prognosis and treatment options. Many of the novel agents used in the treatment of multiple myeloma are being utilized in the treatment of SLCA, and the treatment armamentarium is growing.
- Head and Neck Cancers
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
$0.00
Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.
- Bladder Cancer
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
$0.00
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.